Bionaturis – vaccines

Immunization: great progresses and challenges

The World Health Organization (WHO) is celebrating the Immunization Week with the main goal of promoting vaccination to protect people at all ages from diseases. Since Jenner invented the first vaccine against smallpox at the end of XVIII century, the progresses in the prevention area have saved millions of lives worldwide and they will continue doing it in the future.

According to the WHO, immunization Immunization averts an estimated 2 to 3 million deaths every year from diphtheria, tentanus, whooping cough and measles. Other preventable diseases through vaccination are meningitis, hepatitis B, mumps, poliomyelitis and rubella, among others. Although the immunization coverage is higher and higher in the world, there are still a lot of challenges to achieve. The same institution shows that around 18.7 million of breast-fed babies worldwide in 2014 were not covered by the system of vaccination, because of that it is necessary to double efforts.

Further information about immunization coverage (WHO)

Vaccination is one of the mainstays of the preventive medicine, being the flagship for Medicine at the XXI century. Immunization is a broad field of scientific research for human and animal health. Bionaturis, an international benchmark in the development of biologic vaccines for both sectors, is working in this sphere of knowledge. With the main goal of putting ultimate health technologies and products at a more global reach of customers and users, Bionaturis has developed its alternative platform to produce biological products, FLYLIFE, that offers flexibility, high scale-up speed and less demand of space and investment. Bionaturis has a rich portfolio of biologic products as a vaccine against visceral canine leishmaniosis, another one against nematodes in livestock and other vaccines that prevent several diseases in birds, swines and fish in aquaculture. About human health, the […]

April 26th, 2016|Blog english|Comments Off|

Bionaturis and the US-Biotech company BMI sign an agreement for the jointly development of human and animal vaccines

The goal of this strategic partnership is to join forces to bring to market new and improved biopharmeutical products.

As the first step of this agreement, Bionaturis Group will support the manufacturing development of a first-in-class vaccine to prevent the human common cold.

Jerez, June 18th 2015. Bionaturis Group and Biological Mimetics, Inc., -BMI- (based in Maryland, USA) has started a new strategic collaboration agreement to jointly develop new vaccines for human and animal health applications.

In the context of this agreement Bionaturis Group will use its proprietary FLYLIFE platform for the production of experimental batches of vaccines designed using BMI’s Immune Refocusing Technology (IRT). Specifically, as part of the agreement, Bionaturis Group has begun the works corresponding to the manufacturing proof of concept of a candidate of BMI of a first in man vaccine against Human Rhinovirus, the cause of the common cold as well as primary infant viral pneumonia and its known associations with asthma.

According to the National Center of Health, in the United States there are around 62 million cases annually of common cold with human rhinovirus infection being the culprit for about 35% of them. There are over 100 different types of rhinoviruses, which makes developing a vaccine against rhinoviruses difficult. According to experts, the economic consequences of absenteeism from work, school and primary care services caused by the common cold have an impact, only in the United States economy, between 35 and 40 billion US dollars a year.

The lead of BMI is designed to become the first in man cross serotype vaccine on the market to prevent and/or limit clinical complications from infection. The vaccine is to undergo preclinical and process development and evaluation, carrying out safety, immunogenicity and efficacy trials using […]

June 18th, 2015|Blog english, Press Releases|Comments Off|

Bionaturis takes part in the annual meeting of the European project Targetfish

PhD Ana de las Heras, the person in charge of the Targetfish project within Bionaturis Group, attended the annual meeting of this European consortium intended to develop new vaccines for aquaculture.

During the meeting, held in the Universidad Autonoma of Barcelona, the activities of each of the 30 partners from 13 different countries were reviewed. From Bionaturis Group, Ana de las Heras explained the advances in new vaccine formulations for trout and seabass, being developed along other partners in Targetfish.

Moreover, Targetfish is working on the research of preventive treatments for other species such as salmon, seabream and turbot. All of them the most relevant species in the aquaculture industry in Europe.

A project for excellence

Led by PhD Geert Wiegertjes (Department of Animal Sciences, Cell Biology & Immunology group from Wageningen UR), Targetfish brings together leading European research groups that are experts on the fish immune system and enterprises from the Biotech and Veterinary sectors. This project, to be concluded in the fall of 2017, is funded by the European Commission 7th Framework programme.

If you want to know more about Targetfish, please click here.

November 5th, 2014|Blog english, congress, Press english|Comments Off|

Biotechnology bets on vaccines

The research on vaccines has found a great partner in biotechnology. Nowadays, 30 out of 80 biological products in latest stages of clinical development are biological vaccines to fight currently unmet diseases. According to BIOTECH MAGAZINE, while in Asia and South America the great concern are diseases such as dengue, in Western countries the infections acquired in hospitals (called nosocomial infections) are becoming an increasing problem.

In this way, Bionaturis is taking part in the public-private consortium Adelis, looking for alternatives to traditional antibiotics to tackle the more and more common phenomena of resistance.

Tuberculosis, AIDS, malaria, and leishmaniasis, among others, are diseases for what biotechnology is actively looking for solutions. Hence, Bionaturis is developing a recombinant vaccine against canine visceral leishmaniasis that has already shown efficacy and safety in mice and beagle dogs.

For further information on biotechnology advances on vaccines, please click here

March 25th, 2014|Blog english|0 Comments|

Two out of every three fish dishes will come from aquaculture in 2030

Aquaculture production is currently growing and will continue to do so in the coming years due to a substantial increase in demand. “According to the report ‘ fishing up to 2030: prospects for fishing and aquaculture”, released by the World Bank, the United Nations Organization for food and Agriculture (FAO) and the International Research Institute on food policies (IFPRI), two out of every three fish dishes in 2030 will come from aquaculture. In that year, It´s expected Asia – including Southeast Asia, China and Japan – to represent 70% of the global consumption of fish.

According to the study, both fishing and aquaculture are two important sources of employment and resources for developing countries. However, the diseases affecting aquaculture crop species are one of the main challenges and threats of the sector. To overcome that, Bionaturis works in preventive solutions such as oral vaccines intended to fight the most devastating salmon diseases. The company is also integrated in the European Targetfish project, dedicated to the research and development of preventive solutions for aquaculture, involving 30 partners from 13 different countries.

For further information about the aquaculture report, click here

February 17th, 2014|last news, Press english|0 Comments|

At the begining of the new year, let’s go over the main events for Bionaturis during 2013

As it was forecasted in the business plan, 2013 has been full of activity for Bionaturis, with a much than positive balance in a key area for our business model: the relationship with multinational companies. Thus, during last year Bionaturis has released the signing of three contracts with important veterinarian multinational companies to test its vaccines, such as the one intended to prevent the most devastating diseases of salmons, or the unique vaccine that fight helmints infections in livestock. These agreements have confirmed its position as a global supplier of biological vaccines.

This remarkable position was endorsed in September with the organization, along with “Corporation Tecnologica de Andalucia”, of the Biotech Technical Committee. The event, gathering managers of large laboratories and international experts in the field, was part of the Flylife’s gala day, a manufacturing facility showing one of the highest ratio of biological product production by square meter currently in the market.

In the institutional side, we also highlight that the prestigious Forbes magazine in its last March edition named our CEO, Victor Infante, as one of the 25 young businessmen in Spain to be tracked. Later, in October, he was invited to the extraordinary executive committee of the “Confederation Empresarios de Cadiz”, being chaired by in this special occasion by His Royal Highness Prince Felipe de Asturias, where Infante explained to the attendees the principles, mission and vision of Bionaturis.

2013 has also brought striking news for our investors, ending up the year with a +110% of the annual share price and a remarkable increase of the daily trading volume. That situation has led the BNT-MAB titles to be included in different proposals of investment portfolios for 2014 and it is considered one of the […]

January 3rd, 2014|Blog english, last news, Press english|0 Comments|

VII Innovation Forum in Andalusia: Bionaturis as a successful case

Victor Infante, Bionaturis CEO, participated November 7th in the VII Innovation Forum in Andalusia, which was held at Chamber of Commerce’s facilities in Jerez (Cadiz). Bionaturis, an international reference in developing and producing biological drugs, was presented as a successful case to attendees.

Established eight years ago, Bionaturis is committed from its very beginning on innovation and thus its work in new production platforms of making biopharmaceuticals allows a more global access to them for both producers and patients. It has been listing at the Spanish MAB since January 2012 and has developed a proprietary production system –Flylife-, which allows the production of second generation vaccines using butterfly larvae.

This business forum is part of the InnoCámaras program, which seeks to foster the competitiveness of the SMEs in the region through innovation. More information of the event click here

November 4th, 2013|Blog english, congress, last news, Press english|Comments Off|

Bionaturis will take part on a round table about Andalusian aquaculture R&D

Ana de las Heras, PhD in Veterinarian Sciences and scientist at Bionaturis, will take part on the conference called ‘R&D, an opportunity for the development of aquaculture in Andalusia’ on October 24th , organized by Ifapa (El Toruño Center) and the CAMPUS DE EXCELENCIA INTERNACIONAL DEL MAR” (CEIMAR) of Cadiz University (UCA).

Ana de las Heras will participate in the round table at 14.00 hours along with members of the companies Cupimar and Culmansur.

Check the full program and inscriptions here

October 18th, 2013|congress|0 Comments|

Bionaturis’ FLYLIFE gala day

About thirty managers belonging to different institutions have visited Bionaturis’ FLYLIFE factory this week. The visit was part of the biotech committee of Corporacion Tecnologica of Andalusia (CTA). Reference people of the biotech sector including members of the Brazilian multinational company Ourofino or Bionaturis’ scientific advisor, professor Vikram Vakharia of Maryland University, among others, have been guided by Bionaturis’ staff to know at first hand how thousands of vaccines can be manufactured in no more than 350 square meters. The secret of Flylife is based on the use of butterfly caterpillars as natural factories to get these cutting-edge vaccines, allowing that more people and producers all over the world may have access to them.

About the visit, Javier Gallastegui -managing director of the company- claims “welcoming these personalities and friends and showing them how we take those vaccines to the world from Jerez is an honor for us”. Nowadays, several multinational companies that work in veterinarian field are evaluating vaccines produced by FLYLIFE technology, representing an outstanding milestone for Spanish Biotechnology.

Juan Jose Infante’s speech

Bionaturis, co-organizer of the committee along with CTA, took part with the conference titled ‘Second Generation Vaccines: Bionaturis’ Strategy’, in which the CSO, Juan Jose Infante, talked about the main vaccines being developed by Bionaturis so far. Infante has pointed out the relevance of the innovation in the research of vaccines and how they are key elements not only to human, but also to animal health in order to control devastating pandemics. A sustainable and more affordable manufacturing and developing process is essential to guarantee a broad access to high-benefit vaccines, something that Bionaturis gets with its platform FLYLIFE.

Corporacion Tecnologica of Andalusia (CTA) is a private foundation promoted by the […]

September 12th, 2013|Blog english, last news, Press english|0 Comments|

Vaccines: the best mankind defense

A brief overview to the history of mankind shows the importance of vaccines and, therefore, of preventive medicine research. Although other threats exist nowadays, thanks to science and the development of new manufacturing platform of vaccines as FLYLIFE of Bionaturis, the world is better prepared than ever to halt the spread of either new or the resurgence of some of the most devastating pandemic episodes in history such as the Black Death, flu or smallpox. The invaluable effort of a lot of researchers and experts has it made possible along centuries that these huge pandemics have become history.

Click here to know how it has been achieved

September 2nd, 2013|Blog english, last news, Press english|0 Comments|

12 Next

vaccines

Uso de cookies